Fertility Solutions: Ovulation Inducing Drugs Drive Market Report 2024

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Ovulation Inducing Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $5.7 billion In 2028 At A CAGR Of 6.6% :

The ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.11 billion in 2023 to $4.42 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to development of clomiphene citrate, introduction of letrozole, regulatory approvals and standardization, emergence of ovulation predictor kits..

The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $5.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to changing lifestyles and delayed childbearing, digital health integration, expanding market reach, rising infertility rates, customized treatment regimens.. Major trends in the forecast period include personalized treatment approaches, advancements in reproductive endocrinology, non-invasive fertility monitoring, rising demand for assisted reproductive technologies, development of novel drug formulations..

Request A Sample Of This Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

Ovulation Inducing Drugs Market Major Segments

Key Driver - Rising Prevalence Of Women's Infertility Drives Growth In The Ovulation-Inducing Drug Market

The increasing prevalence of women's infertility is expected to propel the growth of the ovulation-inducing drug market. Women's infertility refers to the biological condition in which a woman cannot conceive a pregnancy or carry it to full term despite engaging in regular, unprotected sexual intercourse for an extended period, typically around a year or more. Ovulation-inducing drugs are used to treat women's infertility to address irregular or absent ovulation issues. These drugs target the hormonal pathways involved in the ovulation process and stimulate the ovaries to release mature eggs. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022, there will be 6.1 million women between the ages of 15 and 44 in the US who have trouble becoming pregnant, equivalent to 10% of all women. Furthermore, in June 2022, according to CCRM Management Company LLC, a US medical management company, infertility affects 1 in 4 couples globally on average, rising by 5% to 10% each year. Therefore, the increasing prevalence of women's infertility drives the growth of the ovulation-inducing drug market.

Customise This Report As Per Your Requirements -
https://www.thebusinessresearchcompany.com/Customise?id=13256&type=smp

Prominent Trend - Increasing Focus On Drug Developments To Drive The Revenues

Major companies operating in the ovulation-inducing drugs market are developing innovative drugs such as Cetrorelix acetate and getting approval to treat women undergoing controlled ovarian stimulation. Cetrorelix acetate for injection (cetrorelix) is a gonadotropin-releasing hormone (GnRH) antagonist. It prevents premature ovulation in women undergoing in vitro fertilization (IVF). For instance, in August 2022, Akorn Operating Company LLC, a US-based pharmaceutical company, received FDA approval for a generic version of cetrorelix acetate for injection, 0.25 mg (Cetrorelix). This is the initial AP-rated bioequivalent Merck Serono Cetrotide variant that has been authorized. Cetrorelix acetate is a GnRH antagonist that acts by blocking the effects of the gonadotropin-releasing hormone (GnRH). GnRH promotes the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Moreover, it is used to prevent premature LH surges in women undergoing controlled ovarian stimulation (COS) and to help ensure that all of the eggs have a chance to mature.

Ovulation Inducing Drugs Market Players
Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter plc, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

View The Full Report Here -
https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the ovulation-inducing drugs market in 2023. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Ovulation Inducing Drugs Market Report Structure
3. Ovulation Inducing Drugs Market Trends And Strategies
4. Ovulation Inducing Drugs Market - Macro Economic Scenario
5. Ovulation Inducing Drugs Market Size And Growth
…..
27. Ovulation Inducing Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.